Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs GH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GH Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

GH Overall Winner 6-Pillar Tally: GRAL 1 – 4 GH (1 Tie) Matrix Metrics: GRAL 3 – 7 GH

As of Nov 16, 2026, Guardant Health, Inc. (GH) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas GH carries 48.4/100 (HOLD) at $144.03 (N/M Forward P/E, -39.4% operating margin).

  • Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. GH 48.4/100 HOLD), GH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-39.4% vs. -332.0% operating margin) and revenue trajectory (+36.1% vs. +3.7% YoY).
  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs GH
GRAL NASDAQ
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
GH NASDAQ Head-to-Head Winner
Guardant Health, Inc. Common Stock
Services-Medical Laboratories
$144.03
-5.06% 1D
Market Cap $20.5B
TTM Revenue $1.28B
Forward P/E N/M
Beta / 30D Vol 1.32β · 56% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 19.0 Fund 48.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.2 · SMA20: $164.87 · SMA50: $168.30

6-Pillar Scorecard Institutional Category Breakdown (GRAL 1 – 4 GH)

Columns: Metric · GRAL · GH
1. Valuation Multiples GRAL
Forward P/E 1.1x N/M
Trailing P/E 1.1x N/M
PEG Ratio N/M N/M
EV / Revenue 31.6x 16.6x
2. Growth & Scale GH
Revenue Growth (YoY) +3.7% +36.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $167M $1.28B
Market Cap $5.2B $20.5B
3. Profitability & Quality GH
Gross Margin 46.7% 65.2%
Operating Margin -332.0% -39.4%
Net Profit Margin -243.8% -37.9%
Return on Equity (ROE) -17.3% 0.0%
4. Balance Sheet & Cash Flow GH
Cash Generation (TTM) -$312M -$232M
Cash Flow Margin N/A -18.2%
Net Cash / Leverage $57M Net Debt (0.03x D/E) $665M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GH
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 93.0% (53rd %ile) 72.2% (31st %ile)
Put/Call OI Skew 0.81x (Call-Skewed) 3.50x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (3) vs GH (7)
Institutional Metric GRAL GH Criterion Row Edge
Market Capitalization
Scale
$5.2B $20.5B Larger Scale GH
Trailing P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% +36.1% Higher Growth GH
Operating Margin (TTM)
Profitability
-332.0% -39.4% Higher Margin GH
Net Profit Margin
Profitability
-243.8% -37.9% Higher Margin GH
Return on Equity (ROE)
Capital Efficiency
-17.3% 0.0% Higher ROE GH
52-Week Range Position
Momentum
51% ($42–$166) 60% ($75–$191) Stronger Trend GH
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol 1.32β · 56% Vol Lower Realized Risk GH
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$167M $1.28B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 65.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev N/M PEG · 16.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) -$232M ($665M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GH +1.17 pp
GRAL: -10.36% · GH: -9.19%
3M Horizon GRAL +61.87 pp
GRAL: +50.96% · GH: -10.91%
6M Horizon GRAL +25.29 pp
GRAL: +77.03% · GH: +51.74%
1Y Horizon GH +26.09 pp
GRAL: +26.92% · GH: +53.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GRAL Revenue GH Revenue GRAL Op. Margin GH Op. Margin Margin Leader
FY2018 N/A $90M N/A -102.5% GH
FY2019 N/A $210M N/A -38.4% GH
FY2020 N/A $290M N/A -88.9% GH
FY2021 N/A $370M N/A -110.0% GH
FY2022 N/A $450M N/A -121.1% GH
FY2023 $90M $560M -1627.6% -100.1% GH
FY2024 $130M $740M -1743.0% -60.0% GH
FY2025 $150M $980M -382.0% -44.5% GH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GH CONSOLIDATION
96d in phase · OBV DISTRIBUTION
Current IV 72.2%
IV Percentile 31st %ile
Put/Call OI Skew 3.50x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GH Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $20.5B market capitalization and -39.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GRAL vs GH Key Questions & Quantitative Answers

As of Nov 16, 2026, Guardant Health, Inc. (GH) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas GH carries 48.4/100 (HOLD) at $144.03 (N/M Forward P/E, -39.4% operating margin). Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. GH 48.4/100 HOLD), GH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-39.4% vs. -332.0% operating margin) and revenue trajectory (+36.1% vs. +3.7% YoY). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GH leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with GH at +36.1% YoY revenue growth and +0.0% YoY earnings growth on $1.28B TTM revenue (65.2% gross margin, -39.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GRAL cumulative revenue shifted +66.7% while GH shifted +988.9%. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GH.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas GH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.6x EV/Revenue (-18.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus GH (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, GH carries 72.2% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 3.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.32β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.